14 October 2016
The Medicines Patent Pool and the World Health Organization’s joint work to forecast the use of antiretrovirals in low- and middle-income countries has been published in peer-reviewed journal PLOS ONE. The paper, which appeared online on October 13, discusses the MPP-WHO forecast of the demand of HIV medicines in developing countries through 2024. Among other analyses, the paper confirms that dolutegravir (DTG), licensed to the MPP from ViiV Healthcare, will be a major player among antiretroviral treatment regimens by 2025, while tenofovir alafenamide (TAF), licensed to the MPP from Gilead Sciences, will witness an increasing market share. Existing ARVs will continue to play a crucial role and their continued supply is critical to sustain international scale-up targets.
The MPP has been forecasting ARV use for more than four years, and in collaboration with the WHO for more than two years. These forecasts have provided broad support to the HIV community and helped guide MPP industry partners in planning their access strategies as well as capacity planning and prioritisation. Forecasts also assist policymakers, procurement agencies, regulatory agencies and other public health stakeholders planning and preparing their policies.
The article’s principal authors include MPP’s business development director Sandeep Juneja and business development manager Aastha Gupta, along with WHO experts Meg Doherty, Daniel Low-Beer, Marco Vitoria, Vincent Habiyambere and Boniface Dongmo Nguimfack.
Read the article
Access MPP’s forecast presentations
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.